outbreak
influenza
repres
first
influenza
pandem
centuri
transmit
million
individu
claim
live
current
statu
mani
countri
prepar
influenza
vaccin
use
cellbas
eggbas
kill
vaccin
howev
tradit
influenza
vaccin
platform
sever
limit
overcom
limit
mani
research
tri
variou
approach
develop
altern
product
platform
one
altern
approach
report
efficaci
influenza
ha
vaccin
use
baculovir
dna
vaccin
achervha
howev
immun
respons
elicit
achervha
vaccin
target
ha
antigen
lower
commerci
kill
vaccin
overcom
limit
previou
vaccin
construct
human
endogen
retroviru
herv
envelopeco
baculovirusbas
viruslikeparticl
vlp
form
dna
vaccin
term
achervvlp
pandem
influenza
balbc
mice
immun
achervvlp
ffu
achervvlp
im
compar
mice
immun
kill
vaccin
mice
immun
achervha
result
achervvlp
immun
produc
greater
humor
immun
respons
exhibit
neutral
activ
intrasubgroup
strain
elicit
neutral
antibodi
product
high
level
secret
splenocyt
diminish
viru
shed
lung
challeng
lethal
dose
influenza
viru
conclus
vlpform
baculoviru
dna
vaccin
could
potenti
vaccin
candid
capabl
effici
deliv
dna
vaccine
vlp
form
dna
elicit
stronger
immunogen
eggbas
kill
vaccin
influenza
viru
notabl
public
health
threat
left
footprint
histori
recent
exampl
outbreak
influenza
repres
first
influenza
pandem
st
centuri
design
influenza
first
case
report
mexico
unit
state
april
june
world
health
organ
declar
level
pandem
accord
global
alert
respons
pandem
infect
million
individu
took
live
despit
toll
wide
believ
influenza
vaccin
import
control
spread
current
licens
influenza
vaccin
eggbas
cellbas
former
constitut
major
vaccin
market
howev
tradit
eggbas
influenza
vaccin
sever
limit
includ
vulner
suppli
chain
necess
select
strain
priori
allerg
reaction
egg
protein
vaccin
often
timeconsum
product
processal
import
issu
need
address
overcom
limit
mani
research
tri
variou
approach
develop
altern
product
platform
one
altern
approach
baculovirus
replic
impos
appar
cytotox
mammalian
cell
thu
minim
possibl
side
effect
baculovirus
clone
capac
larg
kb
allow
accommod
singl
larg
insert
multipl
gene
encompass
regulatori
element
attribut
fuel
interest
explor
baculovirus
vector
recombin
protein
express
system
gene
therapi
spite
advantag
baculoviru
overcom
lower
efficaci
rel
convent
vaccin
remain
challeng
previous
report
nonreplic
baculoviru
vector
contain
antigenencod
dna
could
serv
nanodeliveri
system
improv
exogen
gene
deliveri
human
cell
incorpor
envelop
glycoprotein
human
endogen
retroviru
hervw
recombin
baculoviru
viruslik
particl
vlp
repres
advanc
vaccin
platform
enhanc
immunogen
vlp
form
structur
viral
protein
inher
tendenc
selfassembl
mimic
morpholog
pathogen
contrast
live
virus
vlp
noninfect
nonrepl
sinc
essenti
devoid
pahogenet
materi
moreov
vlp
known
enhanc
immunogen
present
antigen
epitop
correct
conform
result
strong
humor
cellular
immun
respons
given
advantag
vlp
wide
use
vaccin
develop
biomed
applic
previous
confirm
efficaci
influenza
vaccin
develop
dna
deliveri
ha
gene
use
nonreplic
baculovir
vector
achervha
howev
achervha
vaccin
elicit
immun
respons
ha
protein
monoval
may
limit
degre
protect
heterolog
influenza
virus
construct
baculoviru
carri
ha
na
gene
abl
assembl
vlp
mammalian
cell
efficaci
vlpform
baculoviru
vaccineachervvlpwa
test
balbc
mice
studi
perform
strict
accord
guid
care
use
laboratori
anim
nation
institut
health
anim
husbandri
experiment
procedur
approv
konkuk
univers
institut
anim
care
use
committe
iacuc
approv
splenectomi
pneumonectomi
perform
steril
dissect
pan
minim
suffer
mice
sedat
mixtur
tiletamin
xylazin
anesthesia
mgkg
bodi
weight
respect
femal
balbc
mice
g
age
week
n
n
refer
number
anim
mous
vaf
report
indic
mice
free
known
viral
bacteri
parasit
pathogen
purchas
orientbio
seungnam
kyonggido
republ
korea
hous
filter
top
cage
water
food
provid
ad
libitum
mice
maintain
biosafeti
level
facil
invers
hour
daynight
cycl
light
temperatur
humid
control
room
cage
contain
wood
shave
bed
recombin
baculovir
vector
express
herv
env
previous
construct
insert
synthet
codonoptim
envelop
gene
herv
type
w
genbank
access
number
genscript
usa
invitrogen
full
length
ha
na
protein
sequenc
influenza
previous
construct
polymeras
chain
reaction
pcr
amplif
viru
cdna
insert
pgemt
easi
vector
promega
usa
optim
nucleotid
sequenc
protein
sequenc
influenza
achickenvietnam
ncbi
genbank
access
number
gene
codon
optim
optim
express
mammalian
cell
biochem
synthes
genscript
usa
fulllength
ha
na
gene
individu
clone
plasmid
control
cytomegaloviru
cmv
promot
invitrogen
ha
na
gene
cmv
promot
bovin
growth
hormon
bgh
poli
site
amplifi
pcr
clone
plasmid
primer
pcr
shown
tabl
recombin
baculovirus
produc
use
bactobac
baculoviru
express
system
accord
manufactur
manual
invitrogen
scheme
construct
recombin
baculovirus
achervha
achervvlp
shown
fig
propag
cell
amplifi
recombin
baculovirus
supernat
load
top
sucros
purifi
ultracentrifug
rpm
hour
rotor
beckman
coulter
inc
brea
ca
usa
viru
pellet
resuspend
phosphatebuff
salin
pb
store
use
construct
recombin
baculovir
vector
vaccin
confirm
isol
viral
genom
dna
recombin
baculoviru
harvest
infect
cell
use
nucleospin
rna
viru
kit
machereynagel
germani
amplifi
herv
ha
na
gene
pcr
use
primer
shown
tabl
quantif
recombin
baculoviru
carri
recombin
baculoviru
dna
use
qpcr
titrat
kit
takara
clontech
mountain
view
ca
usa
quantifi
pcr
copi
number
per
millilit
ml
convert
focu
form
unit
ffu
ml
accord
manufactur
manual
express
baculoviru
mammalian
cell
test
infect
cell
baculoviru
multipl
infect
moi
seventytwo
hour
infect
western
blot
carri
use
mous
primari
antibodi
dilut
rais
laboratori
surviv
mice
challeng
antibodi
dilut
santa
cruz
biotechnolog
santa
cruz
ca
usa
use
protein
load
control
immunofluoresc
analys
monolay
cell
infect
baculoviru
moi
hour
next
cell
treat
mous
primari
antibodi
dilut
hour
incub
fluorescein
isothiocyan
fitc
conjug
goat
antimous
igg
secondari
antibodi
dilut
santa
cruz
biotechnolog
imag
immunestain
cell
obtain
use
invert
microscop
eclips
tiu
nikon
japan
influenza
vlp
format
mammalian
cell
verifi
harvest
vlp
growth
medium
supernat
lysat
baculovirusinfect
cell
concentr
partial
purifi
use
wv
sucros
step
gradient
phosphat
buffer
salin
pb
purifi
vlp
adsorb
flotat
onto
freshli
discharg
mesh
formvar
carbonco
copper
grid
allow
dri
complet
ted
pella
red
ca
usa
grid
rins
buffer
consist
mm
tri
ph
mm
kcl
neg
stain
uranyl
acet
sigmaaldrich
st
loui
mo
usa
dri
aspir
vlp
visual
transmiss
electron
microscop
jeol
ltd
tokyo
japan
oper
kv
digit
captur
erlangshen
ccd
camera
gatan
inc
pleasanton
ca
usa
fiveweekold
femal
balbc
mice
divid
four
immun
group
n
mice
group
pb
control
kill
vaccin
kill
vaccin
achervha
achervvlp
mice
receiv
two
immun
dose
interv
intramuscular
inject
day
hind
limb
serum
sampl
collect
day
first
immun
day
serum
sampl
obtain
centrifug
whole
blood
collect
right
extern
jugular
vein
also
two
mice
per
group
n
sedat
sacrif
effort
minim
suffer
spleen
remov
day
two
week
final
immun
random
mice
n
transfer
biolog
safeti
level
facil
sedat
mixtur
tiletamin
xylazin
mgkg
bodi
weight
respect
challeng
intranas
lethal
dose
monitor
consecut
day
four
day
infect
subset
mice
n
sacrif
lung
collect
analysi
viral
shed
also
stain
hematoxylin
eosin
h
e
experi
perform
follow
design
experi
timelin
fig
dose
challeng
obvious
result
sever
diseas
character
huddl
ruffl
fur
lethargi
anorexia
lead
weight
loss
death
therefor
mice
monitor
twice
day
case
mice
show
typic
infect
symptom
rapid
weight
loss
percent
within
day
consid
death
mice
show
weight
loss
human
euthan
use
carbon
dioxid
condit
mixtur
tiletamin
xylazin
anesthesia
accord
arriv
guidelin
euthanasia
anim
enzymelink
immunosorb
assay
elisa
perform
assess
specif
igg
level
mous
sera
brief
blood
sampl
collect
mice
sera
obtain
ninetysix
well
plate
coat
overnight
hemagglutin
unit
hau
inactiv
use
standard
method
previous
describ
absorb
nm
measur
use
elisa
plate
reader
biorad
hercul
ca
usa
result
express
reciproc
final
detect
dilut
hemagglutin
inhibit
hai
assay
perform
incub
hau
influenza
viru
dilut
heatinactiv
sera
vbottom
plate
use
chicken
erythrocyt
hai
titer
present
reciproc
highest
dilut
serum
complet
inhibit
hemagglutin
standard
microneutr
assay
modifi
previous
describ
procedur
briefli
serum
sampl
heatinactiv
minut
serial
dilut
prepar
volum
serum
free
mem
v
diluent
immunoassay
plate
dilut
sera
mix
equal
volum
v
diluent
contain
influenza
viru
median
tissu
cultur
infect
dose
tcid
incub
mixtur
transfer
duplic
well
mdck
cell
grown
tissu
cultur
plate
viru
control
well
exhibit
advanc
virusinduc
cytopath
effect
cpe
hour
neutral
capac
individu
serum
sampl
assess
determin
presenc
absenc
cpe
stain
crystal
violet
solut
formaldehyd
methanol
minut
neutral
antibodi
titer
express
reciproc
highest
dilut
serum
complet
inhibit
virusinduc
cpe
product
splenocyt
immun
mice
detect
elispot
assay
kit
bd
bioscienc
usa
san
jose
ca
describ
manufactur
briefli
plate
coat
mous
captur
antibodi
block
fb
splenocyt
cell
medium
appli
well
stimul
inactiv
influenza
viru
addit
hour
plate
wash
treat
ng
biotinyl
mous
detect
antibodi
hour
streptavidinalkalin
phosphatas
ad
well
color
develop
use
aec
substrat
reagent
bd
bioscienc
number
spot
count
use
elispot
reader
aid
elispotread
aid
gmbh
germani
four
day
challeng
mice
n
sacrifi
lung
tissu
collect
ml
pb
contain
gentamycin
collect
lung
homogen
approxim
minut
use
handheld
tissu
homogen
biospec
product
bartlesvil
ok
usa
centrifug
remov
debri
supernat
serial
dilut
transfer
mdck
cell
monolay
tissu
cultur
plate
incub
day
viru
titer
calcul
use
reedmuench
formula
express
tcid
per
millilit
statist
analys
perform
use
graphpad
softwar
graphpad
softwar
inc
la
jolla
ca
usa
data
present
mean
standard
error
mean
sem
percentag
analysi
signific
differ
use
oneway
analysi
varianc
anova
twotail
student
ttest
p
valu
equal
less
consid
statist
signific
effici
express
ha
na
baculoviru
mammalian
cell
construct
hervencod
baculoviru
express
ha
na
gene
control
promot
bacmid
dna
fig
correct
insert
gene
recombin
baculovirus
confirm
pcr
amplif
baculovir
genom
dna
fig
cellderiv
baculovirus
contain
ha
gene
vlp
form
gene
achervha
achervvlp
transduc
cell
ha
protein
express
virusinfect
cell
detect
western
blot
fig
protein
express
baculovirusinfect
cell
confirm
immunofluoresc
stain
use
mous
polyclon
antibodi
fluorescein
isothiocyan
fitc
conjug
antimous
antibodi
fig
collect
result
demonstr
protein
success
express
cell
infect
baculovirus
influenza
vlp
format
mammalian
cell
confirm
compar
neg
stain
achervvlp
wildtyp
posit
control
use
transmiss
electron
microscopi
reveal
larg
spheric
envelop
particl
consist
nm
diamet
fig
investig
immunogen
achervvlp
collect
immun
mous
sera
ten
randomli
select
sampl
group
analyz
titer
igg
elisa
shown
fig
specif
igg
produc
vaccin
group
first
immun
second
immun
compar
analysi
show
igg
titer
higher
achervvlpimmun
mice
achervhaimmun
mice
compar
mice
immun
kill
vaccin
immunofluoresc
micrograph
rbvinfect
cell
seventytwo
hour
infect
cell
incub
mous
antibodi
follow
incub
fitcconjug
goat
antimous
igg
antibodi
mock
acmnpvinfect
cell
achervha
achervhainfect
cell
achervvlp
achervvlpinfect
cell
merg
merg
imag
transmiss
electron
microscopi
neg
stain
purifi
vlp
rbvinfect
cell
seventytwo
hour
infect
vlp
harvest
cell
concentr
partial
purifi
use
step
sucros
gradient
ultracentrifug
electron
microscopi
vlp
stain
uranyl
acet
scale
bar
nm
nm
wildtyp
purifi
influenza
viru
achervha
purifi
vlp
achervhainfect
cell
achervvlp
purifi
vlp
achervvlpinfect
cell
test
crossreact
sera
immun
mice
perform
hai
assay
use
homolog
strain
intrasubgroup
strain
vaccin
immun
group
except
pb
control
show
hai
antibodi
titer
homolog
expect
immun
achervvlp
enhanc
hai
antibodi
respons
compar
immun
achervha
fig
interestingli
achervvlpimmun
mice
show
high
hai
respons
intrasubgroup
strain
fig
confirm
result
determin
neutral
titer
immun
mous
sera
eight
randomli
select
sampl
group
similar
hai
respons
neutral
titer
sera
higher
mice
immun
achervvlp
mice
immun
achervha
viru
viru
respect
fig
data
indic
achervvlp
immun
elicit
strong
humor
immun
respons
show
result
antibodi
greater
neutral
potenti
strain
determin
effect
immun
product
perform
elispot
assay
splenocyt
isol
mice
n
week
final
immun
splenocyt
mice
immun
kill
vaccin
secret
basal
level
similar
result
obtain
mice
inject
pb
fig
howev
splenocyt
mice
immun
baculovirus
achervha
achervvlp
secret
mice
immun
kill
vaccin
comparison
achervha
group
achervvlp
group
show
statist
differ
p
spot
number
achervha
group
lower
number
achervvlp
group
indic
achervvlp
immun
elicit
product
achervha
immun
result
support
conclus
hervencod
vlpform
baculoviru
system
strong
candid
influenza
vaccin
potenti
increas
cellular
immun
respons
well
humor
immun
respons
mice
n
intranas
challeng
dose
infecti
viru
week
immun
weight
loss
health
condit
monitor
consecut
day
challeng
mice
lost
weight
rapidli
initi
day
post
infect
dpi
except
mice
pb
group
subsequ
regain
lost
weight
mice
immun
achervvlp
initi
weight
wherea
mice
achervha
group
show
weight
loss
furthermor
mice
monitor
enter
recoveri
phage
achervvlp
began
recoveri
dpi
wherea
recoveri
delay
dpi
achervha
group
fig
achervvlp
immun
group
show
complet
protect
live
influenza
viru
challeng
achervha
group
show
protect
expect
protect
observ
pb
group
collect
result
indic
achervvlp
provid
better
protect
achervha
due
enhanc
immunogen
humor
immun
respons
cellular
immun
respons
fig
assess
relationship
viral
clearanc
histolog
lesion
lung
sacrif
subset
mice
group
n
day
post
challeng
determin
serolog
analysi
mice
immun
kill
vaccin
baculovirus
sera
mice
inject
intramuscularli
pb
kill
vaccin
achervha
achervvlp
collect
evalu
immun
respons
antigenspecif
igg
antibodi
titer
mous
sera
day
determin
elisa
refer
absorb
nm
b
hai
titer
strain
strain
mous
sera
day
c
neutral
titer
strain
strain
mous
sera
day
elisa
hai
assay
perform
use
ten
randomli
select
sampl
group
neutral
assay
perform
use
eight
randomli
select
sampl
group
valu
parenthes
indic
number
mice
testedtot
number
mice
immun
group
experi
run
triplic
data
shown
mean
sem
sampl
statist
titer
shed
viru
lung
assess
lung
damag
viru
titer
determin
quantifi
infect
mdck
cell
express
log
tcid
ml
viru
titer
pbsinject
mice
wherea
mice
immun
kill
vaccin
achervha
respectivelyapproxim
reduct
viral
titer
strikingli
titer
shed
virus
mous
lung
group
immun
achervvlp
even
lower
overal
reduct
viral
titer
close
fold
tabl
consist
viral
titer
result
histolog
analys
h
estain
lung
section
reveal
mice
inject
pb
alon
sever
infiltr
vessel
bronchiol
alveoli
even
mice
immun
kill
vaccin
achervha
show
interstitialalveolar
infiltr
structur
damag
around
bronchiol
vessel
fig
howev
mice
immun
achervvlp
less
interstiti
alveolar
infiltr
suggest
protect
structur
viral
infect
fig
recent
trend
influenza
vaccin
develop
follow
two
gener
path
univers
vaccin
approach
use
stalk
domain
induc
broadspectrum
neutral
antibodi
specif
approach
use
vlp
addit
advantag
improv
safeti
strong
immun
respons
vlp
vaccin
readili
substitut
ha
na
gene
allow
rapid
dynam
respons
new
influenza
outbreak
howev
effici
construct
product
vlp
major
obstacl
commerci
analysi
show
data
signific
p
signific
one
way
anova
twotail
student
ttest
kill
vaccin
acherv
ha
group
compar
acherv
vlp
group
day
product
mice
immun
kill
vaccin
baculovirus
two
week
final
immun
splenocyt
mice
inject
intramuscularli
pb
kill
vaccin
achervha
achervvlp
collect
evalu
number
secret
spot
cell
splenocyt
elispot
assay
perform
use
two
randomli
select
sampl
group
valu
parenthes
indic
number
mice
testedtot
number
mice
immun
group
experi
run
triplic
data
shown
actual
number
spot
scatter
dot
mean
valu
line
statist
analysi
show
data
signific
p
anova
twotail
student
ttest
kill
vaccin
acherv
ha
group
compar
acherv
vlp
group
previous
report
efficaci
influenza
ha
vaccin
use
herv
encoatedbaculovir
dna
vaccin
achervha
show
immunogen
gene
deliveri
excel
nonetheless
fact
vaccin
deliv
ha
gene
could
expect
elicit
broadspectrum
neutral
antibodi
question
matrix
protein
research
essenti
vlp
form
compon
especi
part
report
induc
broad
rang
crossreact
incorpor
differ
subtyp
ha
protein
na
protein
result
mix
influenza
vlp
provid
protect
influenza
virus
differ
subtyp
therefor
investig
mix
vlp
form
combin
gene
strain
achickenvietnam
full
length
ha
na
gene
strain
construct
vlpform
genedeliv
herv
encoatedbaculoviru
achervvlp
essenti
kill
two
bird
one
stone
achervvlp
transduct
mammalian
cell
hek
cell
vlp
purifi
confirm
transmiss
electron
microscop
fig
result
suggest
construct
baculoviru
capabl
deliv
vlp
form
dna
hek
cell
vlp
form
directli
insid
cell
thu
achervvlp
addit
advantag
product
process
due
extra
purif
vlp
follow
immunogen
efficaci
studi
mice
serolog
analysi
show
achervvlp
immun
elicit
stronger
immunogen
achervha
humor
immun
respons
fig
also
among
sera
obtain
various
immun
mice
sera
achervvlpimmun
mice
exhibit
crossreact
strain
homolog
ha
na
protein
respect
fig
gener
vlp
ident
structur
viru
function
mimic
antigen
henc
advantag
vlp
vaccin
describ
conform
way
especi
present
optim
neutral
epitop
ha
also
achervvlp
includ
protein
vlp
compon
recent
public
indic
protein
contain
highli
conserv
epitop
influenza
viru
induc
crossreact
thu
achervvlp
induc
enhanc
antibodi
respons
homolog
heterolog
wherea
achervha
could
notabl
crossreact
observ
b
type
influenza
viru
data
shown
lack
correl
gene
mix
vlp
broad
crossreact
might
suggest
combin
gene
strain
full
length
ha
na
gene
strain
wellmatch
induc
broadspectrum
humor
immun
respons
baculoviru
dna
deliveri
system
therefor
sought
key
enhanc
breadth
neutral
spectrum
achervvlp
inclus
pivot
immunogen
gene
exampl
shown
addit
extracellular
domain
matrix
protein
sever
ha
gene
increas
breadth
neutral
antibodi
screen
immun
mice
show
achervvlp
immun
induc
stronger
relat
cellular
immun
respons
splenocyt
achervha
immun
indic
vlpform
baculoviru
present
cell
epitop
na
protein
epitop
trigger
stronger
cellular
respons
ha
stimul
whole
kill
influenza
viru
fig
stimul
vlp
form
dna
vaccin
contain
major
cell
epitop
vlp
form
compon
ha
also
influenza
na
protein
conserv
cell
epitop
therefor
vlp
form
achervvlp
present
cell
epitop
cellular
immun
cell
ha
protein
target
achervha
evid
achervvlp
effect
vaccin
provid
observ
challeng
mice
recov
rapidli
infect
show
diminish
viral
shed
lung
fig
fig
tabl
find
provid
support
idea
immun
achervvlp
show
better
protect
pandem
influenza
viru
enhanc
neutral
antibodi
respons
induc
enhanc
secret
addit
baculovir
vector
contain
vlpform
influenza
structur
gene
sever
addit
advantag
includ
eas
manipul
lack
toxic
cost
effect
product
requir
addit
protein
purif
compon
conclus
find
indic
vlpform
achervvlp
vaccin
could
consid
new
candid
dna
vaccin
use
new
emerg
influenza
viru
epidem
support
inform
fig
experiment
timelin
balbc
mice
divid
four
immun
group
n
micegroup
pb
control
kill
vaccin
kill
vaccin
achervha
achervvlp
given
im
inject
day
blood
collect
splenectomi
pneumonectomi
perform
respect
two
week
immun
mice
transfer
biolog
safeti
level
facil
sedat
challeng
intranas
mouseadapt
influenza
viru
dose
mice
observ
health
condit
weigh
consecut
day
tiff
file
arriv
guidelin
checklist
pdf
tabl
primer
use
studi
